LMAT vs UFPT

Key Takeaways

• LeMaitre Vascular (LMAT) is a specialized medical device manufacturer focused on vascular surgery with industry-leading net margins of approximately 24% and a strong cash position exceeding $340 million.
• UFP Technologies (UFPT) operates as a contract development and manufacturing organization (CDMO) for single-use medical devices, generating roughly 2.4 times the revenue of LMAT but with lower profitability margins.
• LMAT carries a higher valuation multiple (trailing P/E of approximately 38 versus 29 for UFPT) but compensates with a dividend yield near 0.9%, 14 years of consecutive dividend growth, and significantly lower volatility (beta of 0.52 versus 1.07).
• UFPT has delivered stronger recent price momentum, with a three-month gain of roughly 39% compared to a modest decline for LMAT over the same period, though its one-year return trails LMAT's.
• Both companies operate in the healthcare sector with similar market capitalizations near $2 billion, yet their business models, risk profiles, and growth drivers diverge considerably, making this comparison a study in contrasting approaches to medical device market participation.

Introduction

Investors navigating the healthcare and medical device landscape often encounter companies that, at first glance, appear broadly similar but diverge sharply upon closer inspection. LMAT (LeMaitre Vascular, Inc.) and UFPT (UFP Technologies, Inc.) represent two such cases. Both are Massachusetts-headquartered healthcare firms with market capitalizations hovering near the $2 billion mark, yet each occupies a distinct niche within the medical ecosystem. This comparison examines how a specialized vascular-device manufacturer stacks up against a contract manufacturing partner to some of the world's largest medical device companies. Whether you are a growth-oriented investor seeking exposure to robotic surgery tailwinds or a value-conscious observer drawn to consistent profitability and shareholder returns, understanding the relative positioning of these two names offers practical insight into current market dynamics.

LMAT Overview and Recent Performance

LeMaitre Vascular designs, manufactures, and markets disposable and implantable vascular devices used primarily by vascular surgeons worldwide. The company's portfolio spans products such as embolectomy catheters, biologic grafts, carotid shunts, and valvulotomes — instruments that address peripheral vascular disease, a condition affecting millions globally. In recent weeks, LMAT shares have traded in the $96 to $106 range, reflecting a stock that has climbed approximately 28% year-to-date while consolidating after reaching its 52-week high near $118.

The company's Q1 2026 results demonstrated continued operational momentum, with earnings per share (EPS) of $0.68 surpassing consensus estimates. This follows a strong fiscal 2025 in which organic sales grew at a mid-teens percentage rate, driven by double-digit gains in catheter and graft product lines. Notably, the international launch of the Artegraft biologic graft has progressed ahead of management's timeline, contributing to above-average growth in the EMEA (Europe, Middle East, and Africa) region. Gross margins have expanded to approximately 70%, reflecting favorable pricing power and manufacturing efficiencies. With roughly $343 million in cash against $186 million in debt, LMAT maintains a fortress-like balance sheet, and its quarterly dividend — recently increased to $0.25 per share — underscores a 14-year track record of returning capital to shareholders.

UFPT Overview and Recent Performance

UFP Technologies functions as a contract development and manufacturing organization (CDMO) that specializes in single-use and single-patient medical devices. Its components and finished devices find application across minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and — increasingly — robotic-assisted surgery platforms. In recent market activity, UFPT shares have demonstrated considerable strength, rising from the $185 area in late April to the $255 level by late July, a gain of roughly 39% over approximately three months.

UFPT's Q1 2026 earnings of $2.48 per share handily beat analyst expectations, and full-year 2025 revenue reached $603 million, representing 19.5% growth over the prior year. The company has been actively expanding its manufacturing footprint, including a growing facility in the Dominican Republic with over 300 employees. Two large robotic surgery programs are in the process of launching into commercial production, with management signaling that each should generate meaningful revenue in 2026 and beyond. Customer concentration remains a relevant consideration: two major clients — Intuitive Surgical and Stryker — accounted for approximately 46% of total net sales in 2025. A cyberattack disclosed in early 2026 disrupted billing and delivery functions but did not materially impact financial systems. The company carries a leaner balance sheet than LMAT, with roughly $18 million in cash against $166 million in debt, and does not pay a dividend.

Trending AI Robots

For traders who prefer data-driven decision-making over manual stock selection, Tickeron's Trending AI Robots page offers a curated gateway into algorithmic trading. Tickeron hosts hundreds of AI-powered trading bots that collectively monitor thousands of tickers across multiple asset classes. These bots vary widely — some are designed for short-term swing trades lasting a few days, while others pursue multi-week trend-following strategies. Each bot carries its own statistical track record, including metrics such as win rate, average return per trade, and maximum drawdown. Only the highest-conviction and most market-adaptive bots earn placement in the Trending AI Robots section, making it a focused resource for traders seeking to observe which algorithms are currently aligned with prevailing market conditions. Whether your interest lies in LMAT, UFPT, or a broader universe of stocks, exploring the Trending AI Robots page can offer a transparent view into what the AI currently favors.

Head-to-Head Comparison

The most fundamental distinction between these two companies lies in their business models. LMAT is a proprietary product company: it develops, brands, and sells its own medical devices directly to surgeons and hospitals, capturing the full margin on each sale. UFPT, by contrast, is an outsourced manufacturing partner — it produces components and devices on behalf of larger medical device companies, earning a narrower but recurring margin on high-volume production runs. This structural difference explains why LMAT's net margin of approximately 24% dwarfs UFPT's roughly 11%, even though UFPT generates more than twice the absolute revenue.

On valuation, UFPT appears optically cheaper with a trailing P/E (price-to-earnings) ratio of roughly 29 versus LMAT's 38. However, that discount partly reflects UFPT's higher beta (1.07 versus 0.52), indicating greater sensitivity to broad market swings, as well as customer concentration risk — the loss of either of its two largest clients would materially dent revenue. LMAT's higher multiple is supported by asset-light economics, recurring consumable revenue streams, and a pristine balance sheet. On growth, UFPT holds the near-term edge: its three-month price surge of roughly 39% outpaces any comparable LMAT rally. Yet over a one-year horizon, LMAT's total return of roughly 27% exceeds UFPT's approximate 5% to 7%, driven partly by dividend contributions and steadier price appreciation. From a sector-exposure standpoint, both reside within healthcare, but LMAT's focus on peripheral vascular disease ties it to demographic aging trends, while UFPT's fortunes are closely linked to surgical volume trends and the capital spending cycles of its largest customers. Risk factors diverge as well: LMAT faces regulatory and competitive risks within a niche device market, while UFPT must manage integration challenges from acquisitions and the operational complexity of multi-site contract manufacturing.

Tickeron AI Verdict

Based on observable trend consistency, financial stability, and relative positioning, Tickeron's AI analytical framework would likely tilt toward LMAT as the more favorable candidate in the current environment, though the comparison is meaningfully nuanced. LMAT's combination of low volatility (beta of 0.52), robust gross margins above 70%, substantial cash reserves exceeding $340 million, and a 14-year dividend growth streak offers a profile that algorithmic models often associate with trend reliability and downside resilience. UFPT's recent momentum is compelling, and its robotic surgery exposure represents a genuine growth catalyst, but the AI would likely weigh the company's customer concentration, narrower margins, and leaner cash position as factors that introduce variability into the trend signal. The probabilistic edge leans toward LMAT for stability-oriented positioning, while UFPT may appeal to models calibrated for higher growth at the cost of greater volatility. As always, the final assessment depends on the specific parameters of any given AI trading bot, and market conditions can shift the balance over time.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations